UBS Group AG Has $2.56 Million Position in Zevra Therapeutics, Inc. $ZVRA

UBS Group AG grew its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 30.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 285,488 shares of the company’s stock after acquiring an additional 67,392 shares during the quarter. UBS Group AG’s holdings in Zevra Therapeutics were worth $2,558,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its position in shares of Zevra Therapeutics by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after purchasing an additional 1,750 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after purchasing an additional 1,812 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares in the last quarter. Sanctuary Advisors LLC boosted its position in shares of Zevra Therapeutics by 18.0% during the 4th quarter. Sanctuary Advisors LLC now owns 34,461 shares of the company’s stock worth $309,000 after purchasing an additional 5,247 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $10.32 on Wednesday. Zevra Therapeutics, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $13.16. The stock has a market cap of $610.07 million, a price-to-earnings ratio of 5.19 and a beta of 0.88. The firm’s 50-day simple moving average is $10.05 and its 200 day simple moving average is $9.26.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The business had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. On average, sell-side analysts predict that Zevra Therapeutics, Inc. will post 0.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. BTIG Research initiated coverage on shares of Zevra Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $23.00 price objective on the stock. Weiss Ratings cut shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Finally, Guggenheim raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $23.33.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.